靶向穿刺与根治性前列腺切除术后分级分期及NCCN风险分层的持续不一致性
单中心回顾性研究纳入140例接受MRI-超声融合靶向穿刺后行根治性前列腺切除术的男性,比较术前MRI与穿刺Gleason分级分组及术后病理的分期和NCCN风险分层。结果显示33.6%患者NCCN风险升高、12.1%降低,25.0%分级升级、22.1%降级、29.3%分期升高;PIRADS 4较PIRADS 3升级风险更低,PSAD≥0.15 ng/mL/cc与分期升高相关。
要点
- 靶向穿刺后约三分之一患者NCCN风险分层较术后病理升高。
- PSAD≥0.15 ng/mL/cc与术后病理分期升高独立相关。
- PIRADS 4患者较PIRADS 3患者Gleason分级升级风险更低。
核心结论
- MRI与靶向穿刺的前列腺癌风险分层与根治性切除术后病理存在持续不一致。
- 需要影像与生物标志物进步以提高治疗前分期的准确性。
研究设计与样本
- 比较术前MRI与穿刺Gleason分级分组及术后病理的分期和NCCN风险分层一致性。
- 多变量回归分析年龄、BMI、PSAD、感兴趣区中位最大径和PIRADS与分级、分期及NCCN风险一致性的关联。
主要发现
- 47例(33.6%)NCCN风险分层较术后病理升高,17例(12.1%)降低。
- 35例(25.0%)Gleason分级分组升级,31例(22.1%)降级。
- 41例(29.3%)术后病理分期升高。
临床怎么用
- 靶向穿刺和MRI风险分层可能低估部分患者病理分级、分期和NCCN风险,临床决策需考虑此不一致。
- PSAD≥0.15 ng/mL/cc提示分期升高风险,可辅助治疗前风险评估。
局限性
- 单中心回顾性设计。
- 样本量140例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To elucidate the accuracy of MRI and MRI-ultrasound fusion guided targeted biopsy (TBx) on risk stratification in men who underwent subsequent radical prostatectomy (RP). MATERIALS AND METHODS: A single-center, retrospective study was performed in men at risk for prostate cancer who (n = 140) underwent TBx and RP between November 2012 and August 2018. Comparisons were made between patients clinically staged by preoperative MRI and TBx Gleason grade group (GGG) and stage after RP. Multivariable regression was performed to identify factors associated with MRI and TBx compared to RP grading, staging, and consistency with National Comprehensive Cancer Network (NCCN) risk stratification. RESULTS: There was an increase in NCCN risk stratification in 47 men (33.6%) and a decrease in 17 men (12.1%) compared to the resected prostate. GGG upgrading and downgrading occurred in 35 (25.0%) and 31 men (22.1%), respectively. Upstaging occurred in 41 men (29.3%). In adjusted analysis for age, BMI, PSA Density (PSAD), median maximal diameter of the regions of interest, and PIRADS, men with PIRADS 4 were less likely to be upgraded (OR 0.26, 95% CI 0.08-0.81, P = .020) than PIRADS 3. PSAD ≥ 0.15 ng/mL/cc was associated with upstaging (OR 3.92, 95% CI 1.60-9.62, P = .003). CONCLUSION: Accurate risk stratification is critical for disease management, mandated by the increasing use of active surveillance, partial gland ablation, and androgen deprivation therapy with radiation therapy for men with unfavorable intermediate and high-risk prostate cancer. This study confirms the need for advances in imaging and biomarker to increase the accuracy of pretreatment staging.
引用
- Alshak MN, Patel N, Gross MD, et al. Persistent Discordance in Grade, Stage, and NCCN Risk Stratification in Men Undergoing Targeted Biopsy and Radical Prostatectomy. Urology. 2019. PMID: 31568795. doi:10.1016/j.urology.2019.07.049
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。